跳至主要内容
临床试验/CTRI/2020/07/026362
CTRI/2020/07/026362尚未招募不适用

CLINICAL EVALUATION OF THE THERAPEUTIC EFFICACY OF SARVAKALPA-GHAN-VATI IN NON-ALCOHOLIC LIVER DISORDER.

Patanjali Research Institute1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2020年7月30日最近更新:

试验速览

阶段
不适用
状态
尚未招募
入组人数
40
试验地点
1
主要终点
normalisation of LFT values

研究概览

简要总结

TRIAL NOT YET STARTED

研究设计

研究类型
Interventional
分配方式
Computer generated randomization
盲法
Not Applicable

入排标准

年龄范围
18.00 Year(s) 至 65.00 Year(s)(—)
性别
All

入选标准

  • Patients between the age group of 18-65 years will be selected.
  • Patients irrespective of sex, religion, occupation and chronicity will be selected for the study.
  • Both fresh and treated cases would be taken for the study.
  • Patients with higher LFT levels than the upper limit of normal value will be selected.
  • Patients with GRADE 1 and GRADE 2 fatty liver will be selected for the study.
  • Patient with controlled Diabetes mellitus having GRADE 1 and GRADE 2 fatty liver will be selected for the study.

排除标准

  • Patients aged <18 years or >65 years will be excluded.
  • Pregnant or lactating women will be excluded.
  • Patients who had hepatitis B, C or other hepatic viral infection, autoimmune hepatitis and drug-induced hepatitis or alcoholic hepatitis will be excluded.
  • Patients with severe complications of the cardiovascular, renal or hematopoietic systems and mental diseases will be excluded.
  • Patients will be excluded having decompensated liver disease.
  • Patients with prolonged or a history of ascites, developed hepato-cellular carcinoma, hepatic encephalopathy, variceal bleeding will be excluded.

结局指标

主要结局

normalisation of LFT values

时间窗: 30 days

次要结局

  • Exacerbation in Signs & Symptoms.(30 days)

研究者

申办方类型
Research institution and hospital

研究点 (1)

Loading locations...

相似试验